Back to Search
Start Over
Molecular epidemiology and expression of capsular polysaccharides in Staphylococcus aureus clinical isolates in the United States
- Source :
- PLoS ONE, Vol 14, Iss 1, p e0208356 (2019), PLoS ONE
- Publication Year :
- 2019
-
Abstract
- Staphylococcus aureus capsular polysaccharides (CP) are important virulence factors under evaluation as vaccine antigens. Clinical S. aureus isolates have the biosynthetic capability to express either CP5 or CP8 and an understanding of the relationship between CP genotype/phenotype and S. aureus epidemiology is valuable. Using whole genome sequencing, the clonal relatedness and CP genotype were evaluated for disease-associated S. aureus isolates selected from the Tigecycline Evaluation and Surveillance Trial (T.E.S.T) to represent different geographic regions in the United States (US) during 2004 and 2009–10. Thirteen prominent clonal complexes (CC) were identified, with CC5, 8, 30 and 45 representing >80% of disease isolates. CC5 and CC8 isolates were CP type 5 and, CC30 and CC45 isolates were CP type 8. Representative isolates from prevalent CC were susceptible to in vitro opsonophagocytic killing elicited by anti-CP antibodies, demonstrating that susceptibility to opsonic killing is not linked to the genetic lineage. However, as not all S. aureus isolates may express CP, isolates representing the diversity of disease isolates were assessed for CP production. While approximately 35% of isolates (primarily CC8) did not express CP in vitro, CP expression could be clearly demonstrated in vivo for 77% of a subset of these isolates (n = 20) despite the presence of mutations within the capsule operon. CP expression in vivo was also confirmed indirectly by measuring an increase in CP specific antibodies in mice infected with CP5 or CP8 isolates. Detection of antigen expression in vivo in relevant disease states is important to support the inclusion of these antigens in vaccines. Our findings confirm the validity of CP as vaccine targets and the potential of CP-based vaccines to contribute to S. aureus disease prevention. Publisher PDF
- Subjects :
- Male
0301 basic medicine
Pulmonology
Physiology
Staphylococcus
Glycobiology
Bacteremia
Tigecycline
Pathology and Laboratory Medicine
medicine.disease_cause
Biochemistry
Mice
INDEL Mutation
RA0421
Nucleic Acids
Immune Physiology
RA0421 Public health. Hygiene. Preventive Medicine
Genotype
Medicine and Health Sciences
Frameshift Mutation
Vaccines
Molecular Epidemiology
Immune System Proteins
Multidisciplinary
Polysaccharides, Bacterial
Middle Aged
Opsonin Proteins
Staphylococcal Infections
Bacterial Pathogens
3. Good health
Infectious Diseases
Medical Microbiology
Staphylococcus aureus
Medicine
Methicillin-resistant Staphylococcus aureus
Female
Pathogens
QR355 Virology
Research Article
medicine.drug
Infectious Disease Control
Science
Immunology
030106 microbiology
Virulence
Biology
Staphylococcal infections
Microbiology
Polymorphism, Single Nucleotide
Antibodies
03 medical and health sciences
Phagocytosis
Antigen
SDG 3 - Good Health and Well-being
Polysaccharides
Operon
Genetics
medicine
Animals
Humans
Operons
Microbial Pathogens
Bacterial Capsules
QR355
Bacteria
Molecular epidemiology
Immune Sera
Organisms
Biology and Life Sciences
Proteins
DAS
DNA
medicine.disease
United States
Biosynthetic Pathways
Disease Models, Animal
030104 developmental biology
Mutation
Respiratory Infections
Subjects
Details
- Language :
- English
- ISSN :
- 19326203
- Database :
- OpenAIRE
- Journal :
- PLoS ONE, Vol 14, Iss 1, p e0208356 (2019), PLoS ONE
- Accession number :
- edsair.doi.dedup.....647411be45224602cf905cb1c70c057e